haploidentical stem cell transplant

BIOLOGICAL2 trials

Sponsors

Masonic Cancer Center, University of Minnesota, National Heart, Lung, and Blood Institute (NHLBI)

Conditions

Acute LeukemiasBurkitt's LymphomaChronic Myelogenous LeukemiaSickle Cell Disease

Phase 1

Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease

Active, not recruitingNCT03077542

National Heart, Lung, and Blood Institute (NHLBI)Sickle Cell Disease

Start: 2017-04-06End: 2026-08-31Updated: 2026-04-23

Unknown Phase

Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases

TerminatedNCT02145039

Masonic Cancer Center, University of MinnesotaAcute Leukemias, Burkitt's Lymphoma, Chronic Myelogenous Leukemia

Start: 2014-10-31End: 2019-01-31Updated: 2019-12-26

Related Papers

Hematopoietic Stem Cell Transplant and Brain Volume Changes in Adults With Sickle Cell Disease.

2026-05-14

Nonmyeloablative pentostatin-cyclophosphamide preconditioning improves rates of engraftment in adults undergoing haploidentical HCT for sickle cell disease.

2026-03-23

Impact of pre-transplant bone marrow cellularity and fibrosis on post-transplant outcomes in sickle cell disease

Blood2025-11-03

In vivo measurement of RBC survival in patients with sickle cell disease before or after hematopoietic stem cell transplantation

Blood Advances2024-01-056 citations

Percent Patient NK and T Cells at Day 28 Predict Graft Outcome after Haploidentical Hematopoietic Cell Transplant for Sickle Cell Disease

Blood2022-11-15